| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/17/2023 | 30.57% | Truist Securities | $46 → $40 | Maintains | Buy |
| 07/28/2023 | 50.16% | Truist Securities | $42 → $46 | Maintains | Buy |
| 07/28/2023 | 40.36% | B. Riley Securities | $48 → $43 | Downgrades | Buy → Neutral |
| 07/18/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 07/14/2023 | 37.1% | Truist Securities | $33 → $42 | Maintains | Buy |
| 05/01/2023 | 20.78% | DA Davidson | $38 → $37 | Maintains | Buy |
| 04/28/2023 | 56.68% | B. Riley Securities | $52 → $48 | Maintains | Buy |
| 04/28/2023 | 7.72% | Truist Securities | $38 → $33 | Maintains | Buy |
| 04/28/2023 | -2.07% | Raymond James | $40 → $30 | Maintains | Outperform |
| 02/21/2023 | 69.74% | B. Riley Securities | $33 → $52 | Upgrades | Neutral → Buy |
| 01/30/2023 | 37.1% | DA Davidson | $44 → $42 | Maintains | Buy |
| 01/27/2023 | 14.25% | Citigroup | $39 → $35 | Maintains | Neutral |
| 01/27/2023 | 7.72% | B. Riley Securities | $35 → $33 | Maintains | Neutral |
| 01/27/2023 | 30.57% | Raymond James | $55 → $40 | Maintains | Outperform |
| 12/15/2022 | 30.57% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 10/28/2022 | 79.53% | Raymond James | $66 → $55 | Maintains | Outperform |
| 10/25/2022 | 4.46% | B. Riley Securities | $44 → $32 | Maintains | Neutral |
| 10/05/2022 | 46.89% | Truist Securities | $50 → $45 | Maintains | Buy |
| 07/29/2022 | 115.44% | Raymond James | $74 → $66 | Maintains | Outperform |
| 07/29/2022 | 40.36% | Citigroup | $42 → $43 | Maintains | Neutral |
| 06/21/2022 | 43.63% | B. Riley Securities | $84 → $44 | Downgrades | Buy → Neutral |
| 04/29/2022 | 141.55% | Raymond James | $70 → $74 | Maintains | Outperform |
| 04/26/2022 | 56.68% | DA Davidson | → $48 | Initiates Coverage On | → Buy |
| 04/19/2022 | 37.1% | Citigroup | $52 → $42 | Maintains | Neutral |
| 01/28/2022 | 128.5% | Raymond James | $67 → $70 | Maintains | Outperform |
| 10/27/2021 | 118.7% | Raymond James | $63 → $67 | Maintains | Outperform |
| 10/14/2021 | 105.65% | Raymond James | $67 → $63 | Maintains | Outperform |
| 07/23/2021 | 118.7% | Raymond James | $68 → $67 | Maintains | Outperform |
| 06/21/2021 | — | B. Riley Securities | Upgrades | Neutral → Buy | |
| 04/23/2021 | 121.97% | Raymond James | $67 → $68 | Maintains | Outperform |
| 03/22/2021 | 118.7% | Raymond James | $48 → $67 | Maintains | Outperform |
| 03/10/2021 | 86.06% | B. Riley Securities | → $57 | Downgrades | Buy → Neutral |
| 01/29/2021 | 56.68% | Raymond James | $40 → $48 | Maintains | Outperform |
| 01/04/2021 | 30.57% | Raymond James | $35 → $40 | Maintains | Outperform |
| 10/29/2020 | 14.25% | Raymond James | $31.5 → $35 | Maintains | Outperform |
| 09/23/2020 | -5.34% | Wolfe Research | → $29 | Initiates Coverage On | → Outperform |
| 07/24/2020 | 2.82% | Raymond James | $23.5 → $31.5 | Maintains | Outperform |
| 06/16/2020 | -23.29% | Raymond James | $22 → $23.5 | Maintains | Outperform |
| 06/03/2020 | -28.19% | Raymond James | $16 → $22 | Maintains | Outperform |
| 05/26/2020 | -21.66% | B. Riley Securities | $19 → $24 | Maintains | Buy |
| 05/18/2020 | -37.98% | B. Riley Securities | $17 → $19 | Maintains | Buy |
| 04/24/2020 | -47.77% | Raymond James | $14 → $16 | Maintains | Outperform |
| 04/24/2020 | -47.77% | SunTrust Robinson Humphrey | $14 → $16 | Maintains | Buy |
| 04/24/2020 | -44.51% | B. Riley Securities | $14.5 → $17 | Maintains | Buy |
| 04/16/2020 | -52.67% | B. Riley Securities | $11.5 → $14.5 | Maintains | Buy |
| 04/14/2020 | -54.3% | SunTrust Robinson Humphrey | $12 → $14 | Maintains | Buy |
| 03/23/2020 | -55.93% | B. Riley Securities | $26.5 → $13.5 | Maintains | Buy |
| 02/18/2020 | -24.92% | Raymond James | → $23 | Upgrades | Market Perform → Outperform |
| 01/27/2020 | -13.5% | B. Riley Securities | $24 → $26.5 | Maintains | Buy |
| 10/30/2019 | — | Longbow Research | Downgrades | Buy → Neutral | |
| 07/30/2019 | -37.98% | Citigroup | $20 → $19 | Maintains | Buy |
| 07/26/2019 | -34.72% | Longbow Research | $21 → $20 | Maintains | Buy |
| 07/22/2019 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2019 | — | Craig-Hallum | Upgrades | Hold → Buy | |
| 11/06/2018 | 1.19% | Citigroup | $23 → $31 | Maintains | Buy |
| 10/31/2018 | -8.6% | Raymond James | $24 → $28 | Maintains | Strong Buy |
| 10/31/2018 | — | CL King | Downgrades | Buy → Neutral |
What is the target price for MarineMax (HZO)?
The latest price target for MarineMax (NYSE: HZO) was reported by Truist Securities on October 17, 2023. The analyst firm set a price target for $40.00 expecting HZO to rise to within 12 months (a possible 30.57% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MarineMax (HZO)?
The latest analyst rating for MarineMax (NYSE: HZO) was provided by Truist Securities, and MarineMax maintained their buy rating.
When is the next analyst rating going to be posted or updated for MarineMax (HZO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MarineMax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MarineMax was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.
Is the Analyst Rating MarineMax (HZO) correct?
While ratings are subjective and will change, the latest MarineMax (HZO) rating was a maintained with a price target of $46.00 to $40.00. The current price MarineMax (HZO) is trading at is $30.64, which is out of the analyst's predicted range.